Who to call at Benitec Biopharma Inc., and when
Fundz watches for the moments Benitec Biopharma Inc. starts buying, and tells you who to reach.
- An alert the day Benitec Biopharma Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Benitec Biopharma Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Benitec Biopharma Inc.. With Fundz connected, it knows.
Benitec Biopharma Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
benitec.comAI Executive Summary
AI-powered analysis of 8-K filing content
Benitec Biopharma's Board appointed Dr. Sharon Mates as an independent Class I director effective November 3, 2025, with a term through the 2026 annual meeting. Her compensation includes stock options valued at $450,000, granted November 5, 2025, that vest at the earlier of the 2026 annual meeting or one year from grant.
Key Takeaways
Dr. Sharon Mates joined the Board as a Class I director effective November 3, 2025, and the Board determined she is independent under Nasdaq rules and the company's Corporate Governance Guidelines.
Her initial equity award is stock options under the 2020 Equity and Incentive Compensation Plan, sized by dividing $450,000 by the Nasdaq closing price on the November 5, 2025 grant date.
3 more takeaways
Related Filings (5)
5 more filings from Benitec Biopharma Inc. in the last 90 days
Filing Overview
What This Means
Benitec Biopharma Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.